Startup profile · funding coverage
Anaconda Biomed funding, valuation and investors
Neurovascular medtech company that closed a $56 million financing to support its pivotal thrombectomy-catheter study.
Keep track of Anaconda Biomed
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Growth financing
$56M · September 23, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$56M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · Barcelona, Spain / Marin, California, USA
Investors in latest funding
Lead: Omega Funds
Other: FOCO , Asabys , Ysios Capital , CDTI
Overview
Anaconda Biomed develops thrombectomy catheters based on its funnel catheter platform. On September 23, 2026 it announced a $56 million financing led by Omega Funds, with FOCO joining and existing investors Asabys, Ysios Capital and CDTI participating.
Why Anaconda Biomed is interesting
A material clinical-stage medtech financing with primary-source disclosure and low-difficulty brand search.
Key facts
- Sep 23, 2026: $56M financing
- Proceeds support the ATHENA pivotal IDE study
Funding history (newest first)
Growth financing
2026-09-23 $56M- Omega Funds (lead)
- FOCO (participant)
- Asabys (participant)
- Ysios Capital (participant)
- CDTI (participant)
Source: https://anaconda.bio/anaconda-biomed-secures-56-million-financing-from-new-and-existing-investors/
Market / IPO context
Editorial / static context — not a live quote.
FAQs about Anaconda Biomed
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.